Vancouver, B.C. – April 27, 2018 – Medipure Pharmaceuticals Inc., a biopharmaceutical incubator committed to discovering and developing proprietary cannabinoid-derived prescription medications, today announced the appointment of industry veteran Dr. Safwat Rabea to its scientific team as Research Scientist – Medicinal Chemistry.
We are so excited to have recently opened a 3,750 square foot research lab on the BCIT campus in Burnaby. This lab is crucial in our quest to help patients worldwide.
As a company we are committed to developing economical non-addictive prescription medications derived from specific cannabinoid molecules. Our core products target key disease areas including pain management, mood disorders/anxiety, nausea, appetite, oncology, arthritis and dermatology. This lab is our first step in fulfilling our dreams.
Vancouver, B.C. – February 6, 2018 – Medipure Pharmaceuticals Inc., a biopharmaceutical incubator committed to discovering and developing proprietary cannabinoid-derived prescription medications, today announced the appointment of industry veteran Dr. Kaiji Hu to its scientific team as Research Scientist - Cell and Molecular Biology.
Medipure Pharmaceuticals has established itself as a biopharmaceutical incubator committed to discovering and developing proprietary cannabinoid-derived prescription medications through state of the art research and development. Medipure is wrapping up an extremely successful 2017 with highlights that include achieving new research milestones, developing new strategic relationships, adding renowned industry leaders to the team, and much more.
Vancouver, BC – December 6, 2017 -
Medipure Pharmaceuticals, a biopharmaceutical incubator committed to discovering and developing proprietary cannabinoid-derived prescription medications, today announced that they are further expanding both their corporate offices in Vancouver and their research labs in Burnaby, B.C., to enhance the Company’s research aimed at developing cannabinoid-derived molecules into non-addictive pharmaceutical drugs.
Vancouver, BC - November 28, 2017 - Medipure Pharmaceuticals, a biopharmaceutical incubator committed to discovering and developing proprietary cannabinoid-derived prescription medications, is pleased to announce the addition of Dr. Gerald Zamponi to the company’s Scientific Advisory Board.
Medipure Pharmaceuticals Inc.: History and Developments
Every day, millions of people around the world suffer with chronic pain, anxiety and skin conditions, greatly affecting their quality of life. At Medipure Pharmaceuticals Inc., we believe that this suffering can be alleviated. That’s why we specialize in researching, developing, testing and marketing new pharmaceutical drugs aimed at reversing chronic pain/anxiety and skin conditions, as well as reducing both the elevated costs and unpredictable side effects of existing medication and techniques.
Make no mistake – North America is in the midst of a prescription drug crisis. Dominated by an addiction to opioids, prescription drug overdoses claim the lives of well over 100 North Americans per day, making them more deadly than traffic accidents or gun violence. The USA and Canada are the number one and two users of opioids in the world, responsible for more than 80% of global consumption with less than 5% of the population. Clearly, North Americans have a problem with opioid abuse. How did things get so bad?
The Birth of an Epidemic
Dr. Andrea Furlan, Associate Professor of Medicine at the University of Toronto, commented recently that pain management is at the core of Canada’s opioid crisis and the key to a solution.
In an article originally published in "The Conversation", an independent and non-profit Academic Journal and reprinted in the National Post, Dr. Furlan noted that two people die every day in Ontario from an opioid overdose. The prevalence of opioids and the physician’s prescription notepad share the responsibility.